Do Statins Reduce Plaque or Just Stabilize It?

Statins do both. They measurably shrink atherosclerotic plaque, and they remodel what remains into a form far less likely to rupture and cause a heart attack. The shrinkage, though, is modest even at high doses, which is why researchers increasingly emphasize the stabilization side of the equation. The distinction matters because a plaque that stays the same size but becomes structurally tougher and less inflamed can be just as protective as one that gets smaller.

What Changes Inside the Plaque

To understand why “just stabilizing” is not a consolation prize, it helps to know what makes a plaque dangerous in the first place. The plaques most likely to rupture and trigger a heart attack tend to have a large, soft lipid core, a thin fibrous cap covering that core, and heavy infiltration by immune cells that chew away at the cap’s structural integrity. Statins alter every one of those features.

A landmark study comparing carotid plaques from patients on pravastatin with plaques from untreated patients found striking differences: the statin-treated plaques had roughly a third as much lipid, about half the macrophage and T-cell infiltration, lower levels of the enzymes that degrade structural proteins, and substantially more collagen holding the cap together.¹ In practical terms, the treated plaques were tougher, less inflamed, and far less likely to crack open.

Statins accomplish this partly through cholesterol lowering and partly through direct effects on the artery wall. They slow the conversion of immune cells called monocytes into the macrophages that gorge on cholesterol inside the plaque. They reduce production of inflammatory signaling molecules and adhesion molecules that recruit more immune cells. These so-called pleiotropic effects operate through pathways related to isoprenoid metabolites, small molecules involved in cellular signaling that statins suppress as a side effect of blocking cholesterol synthesis.²

How Much Plaque Actually Shrinks

The idea that statins can reverse plaque buildup, not just slow it, was once controversial. It is now well supported by imaging studies, though the magnitude is smaller than many patients expect. A systematic review pooling data from 29 studies found that lipid-lowering therapy significantly reduced total plaque volume as measured by intravascular ultrasound, with a parallel reduction in the percentage of the artery occupied by plaque.³ These are real, reproducible reductions, but they are not dramatic.

One review noted that even high-dose statins produce only a small decrease in plaque volume, which is exactly why researchers began looking beyond volume to other statin effects on plaques.⁴ Dose intensity matters. A multicenter study using CT angiography found that intensive statin therapy produced clear annual regression in total plaque volume, while moderate-dose therapy slowed progression significantly but produced less outright shrinkage, and untreated patients saw their plaques grow.⁵

High-intensity rosuvastatin therapy in patients who had just suffered a heart attack showed plaque regression in about three-quarters of treated arteries over 13 months, with the percentage of artery occupied by plaque falling by roughly one percent.⁶ One percent sounds trivial, but these numbers play out across millions of patients and years of exposure. Even small shifts in the right direction add up.

Baseline cholesterol levels also influence how much regression you get. Patients starting with moderate or high cholesterol saw their plaque volumes decrease on statins, but those who already had low cholesterol at baseline actually saw plaque volumes creep upward, suggesting the drug had less raw material to work with.⁷

Thickening the Cap That Keeps Plaques From Rupturing

If you could choose between a slightly smaller plaque with a paper-thin cap and a slightly larger plaque with a thick, reinforced cap, the thicker cap wins every time. Cap rupture is the immediate trigger for most heart attacks and many strokes, and statins have a measurable effect on cap thickness that shows up within weeks.

The EASY-FIT study used optical coherence tomography, a high-resolution imaging technique, to measure fibrous cap thickness before and after atorvastatin treatment. Patients on the higher dose saw their caps thicken by about 69%, compared with 17% on the lower dose.⁸ The ESCORT study found that starting a statin early after an acute coronary event increased fibrous cap thickness within just three weeks, while patients who started later actually saw their caps thin over the same period.⁹ That speed matters in the hospital setting, where an unstable plaque can rupture again at any time.

Ruptured plaques were also far less common in patients already on established statin therapy in one imaging study, appearing in about 8% of statin users versus 36% of non-users.¹⁰ The combined picture is clear: statins make the cap thicker and rupture less likely, and they do it relatively quickly.

The Calcification Paradox

Patients sometimes worry when a CT scan shows more coronary calcium after years on a statin. It looks like the disease is getting worse. In reality, what statins do to plaque composition is more like turning a soft, volatile mixture into something resembling concrete, and that shift is protective.

CT angiography data show that statins reduce the volume of low-attenuation plaque (the soft, lipid-rich kind most prone to rupture) and fibro-fatty plaque, while simultaneously increasing the volume of dense calcium within the plaque.¹¹ A separate serial CT study of statin-treated patients also found that non-calcified plaque volume dropped substantially in statin users, by about 48 cubic millimeters on average, while calcium showed a non-significant trend upward.¹² The net result was a large reduction in total plaque volume despite the calcium increase.

This is sometimes called “favorable calcification.” Dense calcium within a plaque acts like rebar in concrete: it makes the structure rigid and resistant to the mechanical forces that cause rupture. A narrative review of the evidence concluded that while high-dose statins can increase coronary artery calcium scores, those increases are associated with higher plaque stability and a lower risk of cardiovascular events.¹³ The same phenomenon has been described in elderly patients on intensive lipid-lowering therapy, whose calcified plaque volume grew but whose dangerous lipid-rich and fibro-fatty volumes shrank.¹⁴

If your calcium score rises on a statin, that alone is not evidence of treatment failure. It may be evidence that the drug is doing exactly what you want: converting volatile plaque into inert scar tissue.

High-Intensity Statins Quiet Inflammation More Effectively

Inflammation inside the artery wall drives every stage of plaque development, from initial fatty streak to final rupture. Statins suppress that inflammation, but the dose has to be high enough. A meta-analysis of clinical trials using PET imaging to measure arterial wall inflammation found that high-intensity statin therapy significantly reduced uptake of the radiotracer used to mark active inflammation, while low-to-moderate-intensity therapy did not produce a significant reduction.¹⁵

A single-center study in patients with acute coronary syndrome reinforced this finding: moderate-intensity statin therapy lowered LDL cholesterol substantially but failed to reduce plaque inflammation at one month, as measured by PET imaging.¹⁶ Cholesterol went down; inflammation did not. The implication is that the anti-inflammatory benefits of statins, one of the main drivers of plaque stabilization, require higher doses than the lipid-lowering effects alone. This is one reason guidelines have shifted toward recommending high-intensity statins for patients at the highest cardiovascular risk.

The LDL Threshold Where Plaques Stop Growing

There appears to be a specific LDL cholesterol level below which plaques begin to shrink rather than grow. A long-term intravascular ultrasound study of patients with left main coronary artery disease found a consistent relationship between LDL cholesterol and plaque behavior, with an LDL level of about 75 mg/dL as the cutoff below which plaque regression could be expected on average.¹⁷ Above that level, plaques tended to progress. Below it, they tended to regress. Higher HDL cholesterol also helped independently.

This threshold helps explain why moderate-dose statins sometimes halt progression without reversing it: they may get LDL close to 75 but not below it. It also explains why combining statins with other lipid-lowering drugs can tip the balance toward regression, a point the next section explores.

Combination Therapies Push Regression Further

When statins alone do not drive enough regression, adding a second drug can close the gap. Two classes stand out: ezetimibe, which blocks cholesterol absorption in the gut, and PCSK9 inhibitors, which dramatically lower LDL by keeping receptors that clear LDL active on liver cells.

The PRECISE-IVUS trial compared atorvastatin alone with atorvastatin plus ezetimibe and found that about 78% of patients on combination therapy showed coronary plaque regression, compared with 58% on atorvastatin alone.¹⁸ A meta-analysis confirmed that the combination significantly reduces total atheroma volume compared with statin monotherapy, though it did not significantly affect fibrous cap thickness.¹⁹

PCSK9 inhibitors, added on top of statins, go further. A meta-analysis found they significantly reduced both total and percentage atheroma volume, increased fibrous cap thickness, and reduced the lipid arc within plaques compared with statins alone.²⁰ A separate pooled analysis found that PCSK9 inhibitors combined with statins reduced percentage atheroma volume by about one additional percentage point and total atheroma volume by about 6 additional cubic millimeters beyond what statins achieved alone.²¹ In other words, the combination hits both the size and the composition of plaques harder than statins can manage on their own.

Why Some People Do Not Respond

Not everyone’s plaques cooperate. Despite good adherence and significant LDL lowering, some patients see their plaques progress anyway. An imaging study found that the patients most likely to be “statin nonresponders” were those who started with the heaviest plaque burden, including high-risk plaque features like large lipid cores and positive arterial remodeling.²² Essentially, if the disease is already advanced enough, a statin alone may not be powerful enough to reverse the momentum.

Genetics also play a role. Variants in genes involved in cholesterol metabolism and statin processing can influence how much LDL lowering a given dose achieves, and by extension, how much plaque changes. A systematic review identified polymorphisms in several key genes, including those encoding the enzyme that statins target and the LDL receptor itself, that are associated with differing treatment responses. Some variants improve efficacy while others increase the risk of intolerance or reduced benefit. This variability is part of the push toward more personalized approaches to lipid-lowering therapy.

The clinical significance of plaque regression, regardless of how it is achieved, is real. In a randomized trial, patients whose fatty plaque regressed had substantially fewer cardiac events than those whose fatty plaque progressed, with progressors facing roughly three times the event risk.²³ Regression is not just an imaging curiosity. It tracks with whether people actually have heart attacks.

Sex Differences in How Plaques Respond

Women and men start from different baselines and respond somewhat differently to intensive statin therapy. In data from the SATURN trial, women began with lower plaque burden than men but demonstrated greater percentage atheroma volume regression after maximally intensive statin therapy.²⁴ Female sex was independently associated with regression even after accounting for other variables.

A pooled analysis of multiple trials showed a similar pattern: women had less plaque at baseline but more fibrous content and smaller necrotic cores, and they showed greater regression after treatment that achieved similar LDL levels. The regression benefit was most pronounced in women who reached very low LDL levels, below about 55 mg/dL.²⁵ Imaging data from the REASSURE registry found that women harbored more condensed lipid features alongside smaller plaque volumes, suggesting potentially more modifiable disease overall.²⁶

This is noteworthy because women have historically been undertreated with lipid-lowering therapy compared with men at equivalent risk. The imaging data suggest their plaques may actually respond better, strengthening the argument for aggressive treatment in women who meet guideline thresholds.

What Happens When You Stop Taking Statins

Patients sometimes stop statins because of side effects, cost, or a belief that they have been on the drug long enough. The evidence on what happens next is unsettling, especially in people with unstable disease. An animal study found that withdrawing atorvastatin triggered a rapid rebound in plaque inflammation: within three days, plaques showed surges in macrophages, inflammatory cytokines, and matrix metalloproteinases, the very enzymes that digest the fibrous cap. Connective tissue and collagen within the plaques dropped.²⁷ The plaques effectively reverted toward an unstable, rupture-prone state.

Human data point in the same direction. In patients who stopped pravastatin, inflammatory markers including C-reactive protein and interleukin-6 rose within three days, even though cholesterol levels had not yet changed.²⁸ The inflammation came back before the cholesterol did, suggesting it was the loss of the direct anti-inflammatory effects, not just the return of high LDL, that was driving the rebound. A review of clinical and mechanistic evidence concluded that in patients with acute coronary syndromes, statin withdrawal may be especially hazardous because the anti-inflammatory and anti-thrombotic benefits disappear rapidly and can transiently overshoot in the wrong direction.²⁹

The practical takeaway is straightforward: if you and your doctor decide to stop or switch a statin, the timing and the clinical context matter. Abrupt withdrawal during or shortly after a cardiac event carries real risk. This is also why hospital protocols now generally continue or initiate statins immediately after a heart attack, even before discharge.